Vepdegestrant + PF-07220060 for Breast Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial requires that you do not take certain medications, foods, or supplements that strongly affect specific liver enzymes (CYP3A or UGT2B7) or that can cause heart rhythm issues. It's best to discuss your current medications with the trial team to see if any need to be stopped.
What data supports the effectiveness of the drug Vepdegestrant + PF-07220060 for breast cancer?
Research shows that drugs like palbociclib, which is similar to PF-07220060, when combined with hormone therapy, can help women with certain types of breast cancer live longer without the disease getting worse. Additionally, drugs like elacestrant, which are similar to Vepdegestrant, have shown promise in reducing tumor growth in breast cancer models.12345
What makes the drug Vepdegestrant + PF-07220060 unique for breast cancer treatment?
Vepdegestrant + PF-07220060 is unique because it combines a selective estrogen receptor degrader (SERD) with another agent, potentially offering a novel approach to targeting estrogen receptor-positive breast cancer by degrading the estrogen receptor and inhibiting its signaling, which may be more effective than existing treatments.45678
What is the purpose of this trial?
The purpose of this study is to learn about the safety and effects of giving vepdegestrant along with PF-07220060. Vepdegestrant is studied to see if it can be a possible treatment for advanced metastatic breast cancer. This type of cancer would have spread from where it started (breast) to other parts of the body and would be tough to treat. The study is seeking for participants who have breast cancer that:* is hard to treat (advanced) and may have spread to other organs (metastatic).* is sensitive to hormonal therapy (it is called estrogen receptor positive).* is no longer responding to treatments taken before starting this study.All the participants will receive vepdegestrant and PF-07220060. Both medicines will be taken by mouth. The medicines will be taken at home. The experience of people receiving the study medicines will be studied. This will help see if the study medicines are safe and effective. Participants will continue to take vepdegestrant and PF-07220060 until:* their cancer is no longer responding, or* side effects become too severe. They will have visits at the study clinic about every 4 weeks.
Research Team
Pfizer CT.gov Call Center
Principal Investigator
Pfizer
Eligibility Criteria
This trial is for people with advanced or metastatic breast cancer that's estrogen receptor positive and not responding to prior treatments. Participants should have at least one measurable lesion, be in good physical condition (ECOG PS ≤2), and must have had specific previous therapies including a CDK4/6 inhibitor regimen.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive vepdegestrant and PF-07220060 orally in 28-day cycles until cancer progression or severe side effects
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- PF-07220060
- Vepdegestrant
Find a Clinic Near You
Who Is Running the Clinical Trial?
Pfizer
Lead Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University
Arvinas Estrogen Receptor, Inc.
Industry Sponsor